Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Relaxin-3 (RLN3) is a highly conserved neuropeptide hormone in the relaxin/insulin superfamily, consisting of two chains (A and B), with major expression in the nucleus incertus of the brainstem[1][2][3][4][5]. Functioning primarily through the relaxin family peptide 3 receptor (RXFP3), relaxin-3 is a key modulator of arousal, stress response, feeding/metabolism, and cognitive processes, with broad neuronal projections throughout the extended limbic system and septohippocampal pathways[1][2][3][4]. Its role in the central nervous system implicates it as a promising target for neuropsychiatric, stress-related, and metabolic disorders, including depression, anxiety, and addiction, with ongoing research into RXFP3 agonists and antagonists as potential therapeutic agents [1][2][3][4][5].
Agonists: Mimic relaxin-3 action on RXFP3 receptor, activating downstream signaling involved in neural modulation. Antagonists: Block relaxin-3 activity at RXFP3, potentially modulating stress, feeding, or arousal pathways.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Relaxin-3 (RLN3).